Merck & Schering-Plough Disclose More Details On Their Merger
This article was originally published in The Pink Sheet Daily
Executive Summary
To resolve shareholder suits, info is disclosed about arbitration over Remicade and Simponi, and "deal protection" provisions, among other things.
You may also be interested in...
Schering Likely To Play Up Saphris' Safety In Q4 Launch
Clearance for schizophrenia and bipolar disorder in one fell swoop marks a first in the crowded class of atypical anti-psychotics.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.